<p>根据马里兰州退休与养老金系统最近向证券交易委员会（SEC）提交的文件，该系统在第三季度将其在礼来公司的持股增加了 2.7%。该机构投资者在季度内购买了 1,040 股后，持有该公司 39,879 股股票。礼来公司占马里兰州退休与养老金系统持股的 0.6%，是其第 29 大持仓。截至其最近的 SEC 文件，马里兰州退休与养老金系统在礼来公司的持股价值为 30,428,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>一只长期投资者不应忽视的新股</li>
</ul>
<p>其他机构投资者和对冲基金最近也调整了对该公司的持股。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的持股增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股该公司的股票，价值 60,253,000 美元，在此期间又购买了 41,222 股。Exencial Wealth Advisors LLC 在第三季度将其在礼来公司的股份增加了 189.6%。Exencial Wealth Advisors LLC 现在拥有 17,408 股该公司的股票，价值 13,283,000 美元，在上个季度又购买了 11,396 股。Rede Wealth LLC 在第三季度购买了价值 487,000 美元的礼来公司新股份。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的股份增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值 229,000 美元，在上个季度又购买了 39 股。最后，Central Pacific Bank Trust Division 在第三季度将其在礼来公司的股份增加了 25.8%。Central Pacific Bank Trust Division 现在拥有 8,990 股该公司的股票，价值 6,859,000 美元，在上个季度又收购了 1,843 股。机构投资者和对冲基金拥有该公司 82.53% 的股票。</p>
<h2>分析师评级升级与降级</h2>
<p>几位研究分析师最近对 LLY 股票发布了报告。Jefferies Financial Group 将礼来公司的股票目标价从 976.00 美元提高至 1,300.00 美元，并在 1 月 8 日的研究报告中给予该股 “买入” 评级。Sanford C. Bernstein 在 12 月 19 日的研究报告中重申了对礼来公司的 “跑赢大盘” 评级。National Bankshares 在 12 月 1 日的研究报告中为礼来公司设定了 1,286.00 美元的目标价。摩根士丹利在 11 月 24 日的研究报告中将礼来公司的目标价从 1,171.00 美元提高至 1,290.00 美元，并给予该股 “增持” 评级。最后，Loop Capital 在 11 月 10 日的报告中为礼来公司设定了 950.00 美元的目标价。五位股票研究分析师给予该股 “强烈买入” 评级，十九位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “买入”，共识目标价为 1,174.70 美元。</p>
<ul>
<li>礼来股票因 Ventyx 交易平息 Wegovy 担忧而上涨</li>
</ul>
<p><strong>获取我们最新的 LLY 股票分析</strong></p>
<h2>礼来公司股票上涨 0.5%</h2>
<p>NYSE LLY 的股票在周五开盘价为 1,038.26 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,133.95 美元。该公司的 50 日移动平均线为 1,051.34 美元，200 日移动平均线为 870.84 美元。公司当前比率为 1.55，速动比率为 1.24，债务与股本比率为 1.71。该公司的市值为 9815.5 亿美元，市盈率为 50.80，市盈增长比率为 0.75，贝塔值为 0.35。</p>
<ul>
<li>这只 ETF 证明医疗保健复苏是真实的</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出分析师共识预期的 6.42 美元，超出 0.60 美元。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司本季度的收入同比增长 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指引设定为 23.000-23.700 EPS。股票分析师预计礼来公司今年将发布 23.48 EPS。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。2 月 13 日的股东将获得 1.73 美元的股息。这代表着 6.92 美元的年化股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。除息日期为 2 月 13 日。礼来公司的股息支付比率（DPR）为 29.35%。</p>
<h2>礼来公司新闻汇总</h2>
<p>以下是本周影响礼来公司的主要新闻：</p>
<ul>
<li>积极情绪：Nvidia 合作 — 礼来与 Nvidia 宣布联合投资 10 亿美元建立和装备一个 AI 驱动的研究设施，标志着长期研发加速和药物发现潜在的生产力提升。Nvidia 和 Eli Lilly 正在合作建立一个 10 亿美元的实验室。投资者需要了解的内容。</li>
<li>积极情绪：管线进展 — 礼来报告在中国完成了一项新口服候选药物的 I 期研究，推进其口服 GLP-1 管线，并降低未来在美国以外的监管风险。Eli Lilly 在中国完成 I 期研究，悄然推进新口服候选药物。</li>
<li>积极情绪：口服和肿瘤研发信号 — 关于 olomorasib 胶囊研究和日本 I 期联合试验的更新显示，除了当前的 GLP-1 产品线外，管线势头稳健且多样化。Eli Lilly 的 Olomorasib 胶囊研究为投资者信号稳定的管线进展，礼来通过日本 I 期联合研究推进下一波肥胖管线。</li>
<li>积极情绪：分析师支持和战略重点 — 摩根大通强调心血管 Lp(a) 项目，分析师（如 Jefferies）维持乐观目标，强化了超越肥胖药物的增长叙事。摩根大通：Eli Lilly 强调 Lp(a) 药物作为心血管增长重点。</li>
<li>中性情绪：财报前动能 — 市场指标显示强劲动能和高分析师关注度，财报即将发布，这可能会放大日内波动，但也增加了对财报的依赖。Eli Lilly 股价接近高点，随着财报前动能信号的出现。</li>
<li>中性情绪：投资者评论 — 几篇评论文章认为，考虑到礼来的基本面，近期的下跌是一个买入机会；这些评论有助于情绪，但并不是新的催化剂。是否在 LLY 股票下跌时买入？</li>
<li>消极情绪：FDA 对口服肥胖药 Orforglipron 的延迟 — 报道称监管机构将其决定推迟至四月，给股票施加压力，延长了竞争对手的优势并推迟了潜在销售。Eli Lilly 股价在 FDA 报道延迟肥胖药裁决后下跌。</li>
<li>消极情绪：反垄断/竞争诉讼 — 一家复合药房起诉礼来和诺和诺德，声称两者协调努力限制复合替代品；诉讼风险增加了监管/法律的不确定性。礼来和诺和诺德因复合药房对 GLP-1 药物的主导地位而被起诉。</li>
</ul>
<h2>礼来公司简介</h2>
<p>(免费报告)</p>
<p>Eli Lilly and Company（NYSE: LLY）是一家成立于 1876 年，总部位于印第安纳州印第安纳波利斯的全球制药公司。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。Eli Lilly 在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，公司由总裁兼首席执行官 David A. 领导。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Eli Lilly and Company</li>
<li>华尔街警报：买入 AES</li>
<li>Elon 正在将 SpaceX 上市！$100 的 IPO 前机会！</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>紧急：特朗普刚刚引发 AI 最大的颠覆！</li>
</ul>
<p><strong>想看看其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Eli Lilly and Company（NYSE: LLY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 $1,000 在 Eli Lilly and Company 吗？</h2>
<p>在您考虑 Eli Lilly and Company 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然 Eli Lilly and Company 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

礼来

<p>马里兰州退休与养老金系统在第三季度将其在礼来的持股增加了 2.7%，目前持有 39,879 股，价值 3040 万美元。其他机构投资者也提高了他们的持股比例。分析师对 LLY 的共识评级为 “买入”，目标价格范围在 950 美元到 1300 美元之间。礼来的股票开盘价为 1038.26 美元，1 年最高价为 1133.95 美元。该公司报告第三季度每股收益为 7.02 美元，超出预期，收入为 176 亿美元，同比增长 53.9%</p>

<p>Maryland State Retirement &amp; Pension System increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,879 shares of the company's stock after purchasing an additional 1,040 shares during the quarter. Eli Lilly and Company accounts for 0.6% of Maryland State Retirement &amp; Pension System's holdings, making the stock its 29th biggest position. Maryland State Retirement &amp; Pension System's holdings in Eli Lilly and Company were worth $30,428,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据马里兰州退休与养老金系统最近向证券交易委员会（SEC）提交的文件，该系统在第三季度将其在礼来公司的持股增加了 2.7%。该机构投资者在季度内购买了 1,040 股后，持有该公司 39,879 股股票。礼来公司占马里兰州退休与养老金系统持股的 0.6%，是其第 29 大持仓。截至其最近的 SEC 文件，马里兰州退休与养老金系统在礼来公司的持股价值为 30,428,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>一只长期投资者不应忽视的新股</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently modified their holdings of the company. Lazard Freres Gestion S.A.S. increased its holdings in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock worth $60,253,000 after purchasing an additional 41,222 shares during the period. Exencial Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after buying an additional 11,396 shares in the last quarter. Rede Wealth LLC bought a new stake in Eli Lilly and Company in the 3rd quarter valued at $487,000. Precedent Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Finally, Central Pacific Bank Trust Division boosted its position in shares of Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after acquiring an additional 1,843 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也调整了对该公司的持股。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的持股增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股该公司的股票，价值 60,253,000 美元，在此期间又购买了 41,222 股。Exencial Wealth Advisors LLC 在第三季度将其在礼来公司的股份增加了 189.6%。Exencial Wealth Advisors LLC 现在拥有 17,408 股该公司的股票，价值 13,283,000 美元，在上个季度又购买了 11,396 股。Rede Wealth LLC 在第三季度购买了价值 487,000 美元的礼来公司新股份。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的股份增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值 229,000 美元，在上个季度又购买了 39 股。最后，Central Pacific Bank Trust Division 在第三季度将其在礼来公司的股份增加了 25.8%。Central Pacific Bank Trust Division 现在拥有 8,990 股该公司的股票，价值 6,859,000 美元，在上个季度又收购了 1,843 股。机构投资者和对冲基金拥有该公司 82.53% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research analysts recently issued reports on LLY shares. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, January 8th. Sanford C. Bernstein reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research report on Monday, December 1st. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 24th. Finally, Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday, November 10th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and a consensus target price of $1,174.70.</p>
<div class="lb-trans"><p>几位研究分析师最近对 LLY 股票发布了报告。Jefferies Financial Group 将礼来公司的股票目标价从 976.00 美元提高至 1,300.00 美元，并在 1 月 8 日的研究报告中给予该股 “买入” 评级。Sanford C. Bernstein 在 12 月 19 日的研究报告中重申了对礼来公司的 “跑赢大盘” 评级。National Bankshares 在 12 月 1 日的研究报告中为礼来公司设定了 1,286.00 美元的目标价。摩根士丹利在 11 月 24 日的研究报告中将礼来公司的目标价从 1,171.00 美元提高至 1,290.00 美元，并给予该股 “增持” 评级。最后，Loop Capital 在 11 月 10 日的报告中为礼来公司设定了 950.00 美元的目标价。五位股票研究分析师给予该股 “强烈买入” 评级，十九位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “买入”，共识目标价为 1,174.70 美元。</p>
</div><ul>
<li>Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来股票因 Ventyx 交易平息 Wegovy 担忧而上涨</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 LLY 股票分析</strong></p>
</div><h2>Eli Lilly and Company Stock Up 0.5%</h2>
<div class="lb-trans"><h2>礼来公司股票上涨 0.5%</h2>
</div><p>Shares of NYSE LLY opened at $1,038.26 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm's 50-day moving average is $1,051.34 and its 200-day moving average is $870.84. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $981.55 billion, a PE ratio of 50.80, a price-to-earnings-growth ratio of 0.75 and a beta of 0.35.</p>
<div class="lb-trans"><p>NYSE LLY 的股票在周五开盘价为 1,038.26 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,133.95 美元。该公司的 50 日移动平均线为 1,051.34 美元，200 日移动平均线为 870.84 美元。公司当前比率为 1.55，速动比率为 1.24，债务与股本比率为 1.71。该公司的市值为 9815.5 亿美元，市盈率为 50.80，市盈增长比率为 0.75，贝塔值为 0.35。</p>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>这只 ETF 证明医疗保健复苏是真实的</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business's revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。该公司报告每股收益（EPS）为 7.02 美元，超出分析师共识预期的 6.42 美元，超出 0.60 美元。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司本季度的收入同比增长 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指引设定为 23.000-23.700 EPS。股票分析师预计礼来公司今年将发布 23.48 EPS。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。2 月 13 日的股东将获得 1.73 美元的股息。这代表着 6.92 美元的年化股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。除息日期为 2 月 13 日。礼来公司的股息支付比率（DPR）为 29.35%。</p>
</div><h2>Eli Lilly and Company News Roundup</h2>
<div class="lb-trans"><h2>礼来公司新闻汇总</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响礼来公司的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Nvidia partnership — Lilly and Nvidia announced a joint $1 billion lab to build and equip an AI-enabled research facility, signaling long-term R&amp;D acceleration and potential productivity gains for drug discovery. Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.</li>
<li>Positive Sentiment: Pipeline progress — Lilly reported completion of a Phase 1 study in China for a new oral candidate, advancing its oral-GLP1 pipeline and de‑risking future regulatory steps outside the U.S. Eli Lilly Quietly Advances New Oral Candidate With Completion of Phase 1 Study in China</li>
<li>Positive Sentiment: Oral and oncology R&amp;D signals — Updates on olomorasib capsule study and a Japanese Phase 1 combo trial for next‑wave obesity drugs show steady, diversified pipeline momentum beyond current GLP‑1 franchises. Eli Lilly’s Olomorasib Capsule Study Signals Steady Pipeline Progress for InvestorsLilly Advances Next-Wave Obesity Pipeline With Japanese Phase 1 Combo Study</li>
<li>Positive Sentiment: Analyst backing and strategic focus — JPMorgan highlights cardiovascular Lp(a) programs and analysts (e.g., Jefferies) maintain bullish targets, reinforcing the growth narrative beyond obesity drugs. JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus</li>
<li>Neutral Sentiment: Pre-earnings momentum — Market indicators show strong momentum and high analyst interest ahead of upcoming earnings, which can amplify intraday moves but increases dependence on the print. Eli Lilly Shares Near Highs As Score Flags Momentum Ahead Of Earnings</li>
<li>Neutral Sentiment: Investor commentary — Several opinion pieces argue the recent dip is a buying opportunity given Lilly’s fundamentals; these help sentiment but are not new catalysts. Buy The Dip In LLY Stock?</li>
<li>Negative Sentiment: FDA delay on oral obesity pill Orforglipron — Reports the regulator pushed its decision to April have pressured the stock by extending competitor advantage and delaying potential sales. LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling</li>
<li>Negative Sentiment: Antitrust/competition litigation — A compounding pharmacy sued Lilly and Novo Nordisk claiming coordinated efforts to limit compounding substitutes; litigation risk adds regulatory/legal uncertainty. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Nvidia 合作 — 礼来与 Nvidia 宣布联合投资 10 亿美元建立和装备一个 AI 驱动的研究设施，标志着长期研发加速和药物发现潜在的生产力提升。Nvidia 和 Eli Lilly 正在合作建立一个 10 亿美元的实验室。投资者需要了解的内容。</li>
<li>积极情绪：管线进展 — 礼来报告在中国完成了一项新口服候选药物的 I 期研究，推进其口服 GLP-1 管线，并降低未来在美国以外的监管风险。Eli Lilly 在中国完成 I 期研究，悄然推进新口服候选药物。</li>
<li>积极情绪：口服和肿瘤研发信号 — 关于 olomorasib 胶囊研究和日本 I 期联合试验的更新显示，除了当前的 GLP-1 产品线外，管线势头稳健且多样化。Eli Lilly 的 Olomorasib 胶囊研究为投资者信号稳定的管线进展，礼来通过日本 I 期联合研究推进下一波肥胖管线。</li>
<li>积极情绪：分析师支持和战略重点 — 摩根大通强调心血管 Lp(a) 项目，分析师（如 Jefferies）维持乐观目标，强化了超越肥胖药物的增长叙事。摩根大通：Eli Lilly 强调 Lp(a) 药物作为心血管增长重点。</li>
<li>中性情绪：财报前动能 — 市场指标显示强劲动能和高分析师关注度，财报即将发布，这可能会放大日内波动，但也增加了对财报的依赖。Eli Lilly 股价接近高点，随着财报前动能信号的出现。</li>
<li>中性情绪：投资者评论 — 几篇评论文章认为，考虑到礼来的基本面，近期的下跌是一个买入机会；这些评论有助于情绪，但并不是新的催化剂。是否在 LLY 股票下跌时买入？</li>
<li>消极情绪：FDA 对口服肥胖药 Orforglipron 的延迟 — 报道称监管机构将其决定推迟至四月，给股票施加压力，延长了竞争对手的优势并推迟了潜在销售。Eli Lilly 股价在 FDA 报道延迟肥胖药裁决后下跌。</li>
<li>消极情绪：反垄断/竞争诉讼 — 一家复合药房起诉礼来和诺和诺德，声称两者协调努力限制复合替代品；诉讼风险增加了监管/法律的不确定性。礼来和诺和诺德因复合药房对 GLP-1 药物的主导地位而被起诉。</li>
</ul>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>Eli Lilly and Company（NYSE: LLY）是一家成立于 1876 年，总部位于印第安纳州印第安纳波利斯的全球制药公司。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。Eli Lilly 在北美、欧洲、亚洲及其他地区开展业务和商业活动，服务于发达市场和新兴市场。近年来，公司由总裁兼首席执行官 David A. 领导。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Wall Street Alert: Buy AES</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Eli Lilly and Company</li>
<li>华尔街警报：买入 AES</li>
<li>Elon 正在将 SpaceX 上市！$100 的 IPO 前机会！</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>紧急：特朗普刚刚引发 AI 最大的颠覆！</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 LLY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Eli Lilly and Company（NYSE: LLY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 $1,000 在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Eli Lilly and Company 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eli Lilly and Company 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

礼来公司 $LLY 的股票被马里兰州退休与养老金系统收购